How much funding has Expedition Therapeutics raised?

Expedition Therapeutics has raised $115.0M in total funding, most recently a Series B round.

Who are Expedition Therapeutics's investors?

Expedition Therapeutics's investors include General Atlantic, RA Capital Management, Vivo Capital, Sanofi Ventures, Sofinnova Partners.

Where is Expedition Therapeutics headquartered?

Expedition Therapeutics is headquartered in United States.

What industry is Expedition Therapeutics in?

Expedition Therapeutics operates in Biotech, Healthcare.

Expedition Therapeutics

Redefining Care.

United States · $115.0M raised

Biotech

Healthcare

Website: expeditiontx.com
Total Funding: $115.0M

Last Round: $115.0M Series BAug 2026
Rounds: 1

About

Expedition Therapeutics develops treatments for inflammatory and respiratory diseases, with an initial focus on chronic obstructive pulmonary disease (COPD). Its lead program, EXPD-101, is an oral, once-daily DPP1 inhibitor designed to block neutrophil serine protease activation and address neutrophilic inflammation without depleting neutrophils. The company is advancing the candidate into a global Phase 2 COPD trial and sees further potential in bronchiectasis, neutrophilic asthma, and other neutrophil-driven diseases.

Summary

Expedition Therapeutics is a Biotech company based in United States. It has raised $115.0M in total across 1 round, most recently a $115.0M Series B round in Aug 2026. Investors include General Atlantic, RA Capital Management and Vivo Capital.